Page last updated: 2024-11-05

troglitazone and Hyperlipoproteinemias

troglitazone has been researched along with Hyperlipoproteinemias in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.

Research Excerpts

ExcerptRelevanceReference
"Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles."1.31[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Demant, T1

Other Studies

1 other study available for troglitazone and Hyperlipoproteinemias

ArticleYear
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
    Fortschritte der Medizin. Originalien, 2001, Volume: 119, Issue:1

    Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria

2001